Efficacy of ptx3 and posaconazole combination in a rat model of invasive pulmonary aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 6264-6286

  Marra, Emanuele ^a   Sousa, Vitor L ^b   Gaziano, Roberta ^c   Pacello, M Lucrezia ^a   Arseni, Brunilde ^a   Aurisicchio, Luigi ^a   De Santis, Rita ^d   Salvatori, Giovanni ^d  

^a Takis srl   (Italy)

^b Areta International   (Italy)

^c University of Rome âTor Vergata'   (Italy)

^d Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OPSONIN; PENTRAXIN 3; POSACONAZOLE; CYTOCHROME P450; GALACTOMANNAN; MYELOPEROXIDASE; ANTIFUNGAL AGENT; C REACTIVE PROTEIN; SERUM AMYLOID P; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; IMMUNE RESPONSE; INNATE IMMUNITY; LUNG ASPERGILLOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; AUTOPSY; CYTOTOXICITY; DRUG CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; INVASIVE ASPERGILLOSIS; LUNG WEIGHT; MORTALITY RATE; PRIORITY JOURNAL; SURVIVAL; SURVIVAL TIME; THERAPEUTIC INDEX; ANIMAL; INVASIVE PULMONARY ASPERGILLOSIS; MALE;

ANIMALS; ANTIFUNGAL AGENTS; C-REACTIVE PROTEIN; DRUG SYNERGISM; INVASIVE PULMONARY ASPERGILLOSIS; MALE; RATS; SERUM AMYLOID P-COMPONENT; TRIAZOLES;

EID: 84907267770     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/aac.03038-14     Document Type: Article

References (18)

1. Zmeili OS, Soubani AO. 2007. Pulmonary aspergillosis: a clinical update.Q. J. M. 100:317-334. http://dx.doi.org/10.1093/qjmed/hcm035.
2. Latgé JP. 2001. The pathobiology of Aspergillus fumigatus. Trends Microbiol. 9:382-389. http://dx.doi.org/10.1016/S0966-842X(01)02104-7.
3. Burguete SR, Maselli DJ, Fernandez JF, Levine SM. 2013. Lung transplant infection. Respirology 18:22-38. http://dx.doi.org/TO1111/j.1440-1843.2012.02196.x.
4. Marr KA, Carter RA, Crippa F, Wald A, Corey L. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34:909-917. http://dx.doi.org/10.1086/339202.
5. Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. 2012. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob. Agents Chemother. 56:5503-5510. http://dx.doi.org/10.1128/AAC.0080212.
6. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347. http://dx.doi.org/10.1056/NEJXloa061098.
7. Comely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359. http://dx.doi.org/10T056/NEJMoa061094.
8. Introna M, Breviario F, dAniello EM, Golay J, Dejana E, Mantovani A. 1993. IL-1 inducible genes in human umbilical vein endothelial cells. Eur. Heart J. 14(Suppl K):78-81.
9. Garlanda C, Bottazzi B, Bastone A, Mantovani A. 2005. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 23:337-366. http://dx.doi.org/10.1146/annurev.immunol.23.021704.115756.
10. Moalli F, Jaillon S, Inforzato A, Sironi M, Bottazzi B, Mantovani A, Garlanda C. 2011. Pathogen recognition by the long pentraxin PTX3. J. Biomed. Biotechnol. 2011:830421.
11. Inforzato A, Doni A, Barajon I, Leone R, Garlanda C, Bottazzi B, Mantovani A. 2013. PTX3 as a paradigm for the interaction of pentraxins with the complement system. J. Biomed. Biotechnol. Semin. Immunol. 25:79-85.
12. Jaillon S, Peri G, Delneste Y, Fremaux I, Doni A, Moalli F, Garlanda C, Romani L, Gasean H, Bellocchio S, Bozza S, Cassatella MA, Jeannin P, Mantovani A. 2007. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J. Exp. Med. 204:793-804. http://dx.doi.org/10T084/jem.20061301.
13. Gaziano R, Bozza S, Bellocchio S, Perruccio K, Montagnoli C, Pitzurra L, Salvatori G, De Santis R, Carminati P, Mantovani A, Romani L. 2004. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob. Agents Chemother. 48:4414-4421. http://dx.doi.org/101128/AAC.48.ll.4414-4421.2004.
14. Lo Giudice P, Campo S, De Santis R, Salvatori G. 2012. Effect of PTX3 and voriconazole combination in a rat model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 56:6400-6402. http://dx.doi.org/10.1128/AAC.01000-12.
15. Lo Giudice P, Campo S, Verdoliva A, Rivieccio V, Borsini F, De Santis R, Salvatori G. 2010. Efficacy of PTX3 in a rat model of invasive aspergillosis. Antimicrob. Agents Chemother. 54:4513-4515. http://dx.doLorg/10.1128/AAC.00674-10.
16. Daigo K, Yamaguchi N, Kawamura T, Matsubara K, Jiang S, Ohashi R, Sudou Y, Kodama T, Naito M, Inoue K, Hamakubo T. 2012. The proteomic profile of circulating pentraxin 3 (PTX3) complex in sepsis demonstrates the interaction with azurocidin 1 and other components of neutrophil extracellular traps. Mol. Cell. Proteomics 11:M111.015073.
17. Canovi M, Lucchetti J, Stravalaci M, Valentino S, Bottazzi B, Salmona M, Bastone A, Gobbi M. 2014. A new surface plasmon resonance-based immunoassay for rapid, reproducible and sensitive quantification of pentraxin-3 in human plasma. Sensors (Basel) 14:10864-10875. http://dx.doi,org/10.3390/s140610864.
18. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. 2004. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci. 21:645-653. http://dx.doi.org/10.1016/j.ejps.2004.01.005.